tetano
Editor, Senior Moderator
Expert Rev Vaccines. 2020 Jan 4. doi: 10.1080/14760584.2020.1711053. [Epub ahead of print] [h=1]Progress in the development of virus-like particle vaccines against respiratory viruses.[/h]
Quan FS[SUP]1,[/SUP][SUP]2[/SUP], Basak S[SUP]3[/SUP], Chu KB[SUP]3[/SUP], Kim SS[SUP]2,[/SUP][SUP]4[/SUP], Kang SM[SUP]5[/SUP].
[h=3]Author information[/h] 1 Department of Medical Zoology, Kyung Hee University School of Medicine, Seoul 02447, Republic of Korea. 2 Medical Research Center for Bioreaction to Reactive Oxygen Species and Biomedical Science Institute, School of Medicine, Graduate school, Kyung Hee University, Seoul 02447, Republic of Korea. 3 Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea. 4 Department of Biochemistry and Molecular Biology, Kyung Hee University School of Medicine, Seoul 02447, Republic of Korea. 5 Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.
[h=3]Abstract[/h] Introduction: Influenza virus, human respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) are important human respiratory pathogens. Recombinant virus-like particle (VLP) vaccines are suggested to be potential promising platforms to protect against these respiratory viruses. This review updates important progress in the development of VLP vaccines against respiratory viruses.Areas Covered: This review summarizes progress in developing VLP and nanoparticle-based vaccines against influenza virus, RSV and HMPV. The PubMed was mainly used to search for important research articles published since 2010 although earlier key articles were also referenced. The research area covered include VLP and nanoparticle platform vaccines against seasonal, pandemic, and avian influenza viruses as well as RSV and HMPV respiratory viruses. The production methods, immunogenic properties and vaccine efficacy of respiratory VLP vaccines in preclinical animal models and clinical studies were reviewed in this article.Expert Opinion: Previous and current preclinical and clinical studies suggest that recombinant VLP and nanoparticle vaccines are expected to be developed as promising alternative platforms against respiratory viruses in future. Therefore, continued research efforts are warranted.
[h=4]KEYWORDS:[/h] Human metapneumovirus virus; Influenza virus; Protection; Respiratory syncytial virus; Vaccines; Virus-like particles
PMID: 31903811 DOI: 10.1080/14760584.2020.1711053
Quan FS[SUP]1,[/SUP][SUP]2[/SUP], Basak S[SUP]3[/SUP], Chu KB[SUP]3[/SUP], Kim SS[SUP]2,[/SUP][SUP]4[/SUP], Kang SM[SUP]5[/SUP].
[h=3]Author information[/h] 1 Department of Medical Zoology, Kyung Hee University School of Medicine, Seoul 02447, Republic of Korea. 2 Medical Research Center for Bioreaction to Reactive Oxygen Species and Biomedical Science Institute, School of Medicine, Graduate school, Kyung Hee University, Seoul 02447, Republic of Korea. 3 Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea. 4 Department of Biochemistry and Molecular Biology, Kyung Hee University School of Medicine, Seoul 02447, Republic of Korea. 5 Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.
[h=3]Abstract[/h] Introduction: Influenza virus, human respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) are important human respiratory pathogens. Recombinant virus-like particle (VLP) vaccines are suggested to be potential promising platforms to protect against these respiratory viruses. This review updates important progress in the development of VLP vaccines against respiratory viruses.Areas Covered: This review summarizes progress in developing VLP and nanoparticle-based vaccines against influenza virus, RSV and HMPV. The PubMed was mainly used to search for important research articles published since 2010 although earlier key articles were also referenced. The research area covered include VLP and nanoparticle platform vaccines against seasonal, pandemic, and avian influenza viruses as well as RSV and HMPV respiratory viruses. The production methods, immunogenic properties and vaccine efficacy of respiratory VLP vaccines in preclinical animal models and clinical studies were reviewed in this article.Expert Opinion: Previous and current preclinical and clinical studies suggest that recombinant VLP and nanoparticle vaccines are expected to be developed as promising alternative platforms against respiratory viruses in future. Therefore, continued research efforts are warranted.
[h=4]KEYWORDS:[/h] Human metapneumovirus virus; Influenza virus; Protection; Respiratory syncytial virus; Vaccines; Virus-like particles
PMID: 31903811 DOI: 10.1080/14760584.2020.1711053